Test Price
2,500 AED✅ Home Collection Available
Minimal Residual Disease (MRD) Monitoring for B-Cell Chronic Lymphocytic Leukemia (B-CLL) in UAE | 2500 AED
Executive Summary & Core Metrics
Accurate MRD assessment for B-CLL treatment response monitoring in Dubai.
- Diagnostic Sensitivity: 99.9% via ISO 9001:2015 Accredited Multiparametric Flow Cytometry.
- Collection Protocol: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Telephonic post-test consultation for result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
Minimal Residual Disease (MRD) monitoring for B-CLL employs highly sensitive 8-color multiparametric flow cytometry (MFC) to detect residual leukemic cells below the threshold of conventional morphology. This assay enables precise quantification of treatment response, risk stratification, and early identification of molecular relapse, supporting informed therapeutic decisions for patients with B-CLL.
| Feature | MRD Flow Cytometry (Our Service) | Alternative PCR-Based MRD |
|---|---|---|
| Precision | 99.9% sensitivity with 8-color MFC | High, but dependent on clonal marker availability |
| Method | Multiparametric Flow Cytometry (MFC) | Allele-specific oligonucleotide PCR (ASO-PCR) |
| Turnaround Time | 3 Working Days | 5–7 Working Days |
Physician Insight & Safety Protocols
“MRD monitoring serves as a critical barometer for treatment efficacy in B-CLL. While a negative result is encouraging, it must always be interpreted alongside clinical presentation, imaging, and laboratory trends. Patients should maintain regular follow-up with their hematologist and report any new or persistent symptoms without delay.” — Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Medication & Clinical Advisory
⚠️ Important Medication Notice
Do not discontinue or alter any prescribed medication without explicit instruction from your treating physician. Abrupt changes may affect disease control and compromise treatment outcomes.
Exclusion Criteria for MRD Testing
- Active systemic infection (e.g., sepsis, pneumonia)
- Blood transfusion within 48 hours prior to sample collection
- Inability to provide adequate bone marrow aspirate or peripheral blood sample
🚨 Emergency Red Flags – Seek Immediate Medical Attention
- Sudden onset of fever >38.5°C, chills, or drenching night sweats
- Severe bone pain, unexplained bruising, or active bleeding
- Rapidly enlarging lymph nodes, abdominal distension, or splenomegaly
Patient FAQ & Clinical Guidance
1. What is MRD testing for B-CLL and why is it important?
A: Minimal Residual Disease (MRD) testing detects extremely low levels of leukemia cells that may persist after treatment—below what standard microscopy can identify. This helps your oncologist assess how completely the disease has responded, predict relapse risk, and tailor ongoing therapy to improve long-term outcomes.
2. How is the sample collected for MRD monitoring?
A: The procedure requires a bone marrow aspirate (first pull) collected by a qualified physician in a hospital setting, along with a peripheral blood sample. Because bone marrow aspiration is an invasive clinical procedure, collection is performed exclusively within an accredited hospital facility to ensure patient safety and sample integrity.
3. How soon will I receive my MRD results in the UAE?
A: Results are typically delivered within 3 working days after the sample is received by the laboratory. You will receive a WhatsApp notification with a secure link to access your report as soon as it is available for faster turnaround.
4. What documentation do I need to provide for MRD testing?
A: You must supply the following: sample time point relative to chemotherapy cycles, the most recent diagnostic immunophenotype report, complete clinical history along with the test request form (TRF), exact date and time of sample collection, and full details of current therapy. These records ensure accurate result interpretation.
5. Does insurance cover MRD monitoring in Dubai?
A: Coverage depends on your individual insurance policy. We offer direct billing verification—please send a WhatsApp message to +971 54 548 8731 with your insurance details, and our team will confirm eligibility prior to sample collection.
UAE Regulatory & Data Privacy Adherence
All diagnostic data and patient information are processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License Number 1143.
Clinical & Logistical Metadata
| Test Name | Minimal Residual Disease (MRD) Monitoring for B-Cell Chronic Lymphocytic Leukemia (B-CLL) |
| Price (AED) | 2,500 AED |
| Turnaround Time | 3 Working Days (sample accepted daily by 11 am) |
| Sample Type / Matrix | Bone Marrow Aspirate (first pull, 3 mL, green top sodium heparin) & Peripheral Whole Blood (4 mL, 2 green top sodium heparin tubes) plus 2–3 unstained BMA or peripheral smears |
| Methodology Used | 8-Color Multiparametric Flow Cytometry (MFC) |
| ICD-10-CM Code | C91.1 (Chronic lymphocytic leukemia of B-cell type) |
| LOINC Code | 53421-1 (Minimal residual disease panel - Blood or Tissue by Flow cytometry) |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians